WO1997046265A1 - Pansement - Google Patents

Pansement Download PDF

Info

Publication number
WO1997046265A1
WO1997046265A1 PCT/SE1997/000946 SE9700946W WO9746265A1 WO 1997046265 A1 WO1997046265 A1 WO 1997046265A1 SE 9700946 W SE9700946 W SE 9700946W WO 9746265 A1 WO9746265 A1 WO 9746265A1
Authority
WO
WIPO (PCT)
Prior art keywords
wound dressing
wound
dressing according
layer
section
Prior art date
Application number
PCT/SE1997/000946
Other languages
English (en)
Inventor
Staffan Bowald
Gudmund Dvärsäter
Original Assignee
Astra Aktiebolag (Publ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR9709639A priority Critical patent/BR9709639A/pt
Priority to NZ332950A priority patent/NZ332950A/xx
Priority to CA002255627A priority patent/CA2255627A1/fr
Priority to JP10500486A priority patent/JP2000511446A/ja
Priority to PL97330307A priority patent/PL330307A1/xx
Priority to IL12710797A priority patent/IL127107A0/xx
Application filed by Astra Aktiebolag (Publ) filed Critical Astra Aktiebolag (Publ)
Priority to EP97926340A priority patent/EP0906126A1/fr
Priority to AU31128/97A priority patent/AU719419C/en
Publication of WO1997046265A1 publication Critical patent/WO1997046265A1/fr
Priority to IS4898A priority patent/IS4898A/is
Priority to NO985628A priority patent/NO985628L/no
Priority to SE9804184A priority patent/SE9804184L/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0203—Adhesive bandages or dressings with fluid retention members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00927—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00927—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors
    • A61F2013/00931—Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors chitin

Definitions

  • the present invention relates to wound dressings for dressing of wounds on internal or external tissue structures of living human or animal bodies.
  • EP-A-0349505 (Astra Meditec AB) it is taught that the healing of soft tissue in mammals including man can be improved by the use of a porous flexible sheet of a protein-free bioresorbable polymer having a pore size which permits passage of water and salts therethrough but which locks out cells and other tissue particles.
  • the sheet is disclosed as causing a specific stimulating effect on the formation of macrophages in soft tissue, the macrophages releasing a growth factor which stimulates tissue healing.
  • Suitable polymer materials mentioned in EP-A-0349505 for the sheet are those based on polyglycolic acid, copolymers of glycolic acid and lactic acid, copolymers of lactic acid and ⁇ -aminocapronic acid, lactide polymers, polydesoxazon, poIy(3-hydroxybutyrate), copolymers of poly(3- hydroxybutyrate) and 3-hydroxyvalerate, polyesters of succinic acid and cross-linked hyaluronic acid.
  • EP-A-0349505 makes known forming a non-woven sheet of poly(3- hydroxybutyrate) having the requisite properties by pressing together solution-spun fibres of poly(3-hydroxybutyrate) manufactured in accordance with US-A-4603070 (Steel et al).
  • GB-A-2166354 discloses a wound dressing comprising a poly(3-hydroxybutyrate) polymer dissolved or swollen with a volatile solvent such as chloroform, preferably co-polymerised with 3-hydroxyvalerate units.
  • the material is painted onto the wound as a solution or gel to give a thin film of polymer in intimate contact with the treated area.
  • the poly(3-hydroxybutyrate) is stated to be hydrophilic, obviating the need for an outer hydrophilic layer.
  • the dressing is stated to be particularly suitable for rapid protection of a wound site with a temporary covering.
  • the thin layer of hydrophilic poly(3-hydroxybutyrate) disclosed in GB-A-2166354 has a number of disadvantages as a wound dressing. To start with, there is no provision for removal of excess fluid since the layer of poly(3-hydroxybutyrate) is not particularly absorbent and exudate from the wound will not pass through it. Furthermore, it could be difficult to remove the dressing from an open wound and the volatile solvent in it tends to be cell-toxic and could cause irritation of the wound site. Moreover, the pore size distribution created in the poly(3-hydroxybutyrate) layer would be such that the size of the pores closest the wound would be less than the size of the pores remote from the wound. The possibility of infection of the wound through ingress of bacteria to the dressing therefore exists.
  • the prior art has not addressed the problem of providing a convenient wound dressing for use during the gradual healing of wounds that may be conveniendy applied and, where needed, removed, which provides thermal insulation to maintain body temperature in the vicinity of the wound surface and keeps the wound moist yet permits removal of excessive fluid from the wound.
  • the present invention proposes to improve this situation.
  • a wound dressing for dressing a wound on a tissue structure of a living human or animal body comprising a lower section which when the wound dressing dresses the wound is disposed adjacent the wound, the lower section being fluid permeable, for example liquid permeable, and comprising a bioresorbable material which promotes the healing process of the wound, and an upper section which when the dressing dresses the wound overlies the lower section, the upper section being permeable to vapour and impermeable to bacteria.
  • Such a dressing is relatively simple to manufacture. Moreover, the dressing is easy to apply and can be adapted to facilitate easy removal.
  • the dressing furthermore provides thermal insulation to maintain the body temperature in the vicinity of the wound surface and keeps the wound moist while removing excessive fluid from the wound. Ensuring that the upper section is essentially impermeable to bacteria also means that a barrier is presented to prevent infection from occurring.
  • the wound dressing of the invention may be left in place for a relatively long period. This means that fewer changes of dressing are needed than were hitherto, thus avoiding disturbing the healing process with less pain for the patient
  • the use of an upper section which is vapour permeable ensures that the wound is kept moist, irrespective of how effective the removal of excessive fluid from the wound may be. Preventing the wound from drying out results in pain being controlled.
  • the wound dressing is an integral structure.
  • the wound dressing is formed as an integrated structure.
  • the upper and lower sections may respectively be presented by upper and lower wound dressing layers which are coupled to one another prior to dressing of the wound.
  • the wound dressing is formed once the wound is dressed, for example the upper and lower sections are respectively presented by upper and lower wound dressing layers which are applied to the wound separately.
  • Having the lower section of the wound dressing as a lower wound dressing layer, for instance a sheet, means that it can be easily put in position and used as a barrier facilitating the transport of exudate from the wound and retaining it away from the wound.
  • the wound dressing further comprises an intermediate section between the upper and lower sections which is adapted to absorb liquid.
  • the intermediate section may be of any suitable material, for example treated cellulose fibres or polyacrylic acids.
  • a hydrocoUoid is particularly suitable.
  • a hydrocoUoid is normally able to absorb four to six times its own volume of fluid, and new hydrocoUoids have been reported that absorb twenty times their own volume.
  • HydrocoUoids also are adhesive to the skin, so the hydrocoUoid can perform the dual function of intermediate absorbent layer and adhesive edge for the dressing.
  • the intermediate section of the second and third forms of the invention may be in the form of an intermediate wound dressing layer or instead be part of the upper or lower wound dressing layer of the wound dressing.
  • the wound dressing consists of the upper and lower sections with the lower and upper sections comprising the bioresorbable material.
  • the bioresorbable material may be in particulate or fibre form.
  • the wound dressing may comprise particles or fibres of the bioresorbable material in a matrix material such as a gel matrix of hyaluronic acid or the like.
  • the wound dressing may be a fibre sheet of the bioresorbable material, for instance a non- woven fibre sheet
  • one or more of the wound dressing layers are in the form of one or more wound dressing sheets.
  • the wound dressing consists of the upper and lower wound dressing layers with the lower dressing layer being adhered to a lower surface of the upper wound dressing layer.
  • the wound dressing comprises the intermediate wound dressing layer the upper and lower wound dressing layers are respectively adhered to upper and lower surfaces of the intermediate wound dressing layer.
  • the lower wound dressing layer is releasably secured to the balance of the wound dressing.
  • the lower wound dressing layer may be releasably secured to the lower surface of the upper wound dressing layer or the lower surface of the intermediate wound dressing layer.
  • the lower section of the wound dressing is substantiaUy free of volatile solvent
  • the lower wound dressing layer is presented by a layer of particles of the bioresorbable material.
  • the particles may be supported in a matrix material, for example a gel matrix comprising hyaluronic acid.
  • the bioresorbable particulate material of the lower wound dressing layer is adhered to the lower surface of the upper or intermediate wound dressing layer by mixing the particles in a solvent, coating the mixture to the lower surface and then evaporating the solvent.
  • Chloroform may be mentioned as a suitable solvent
  • the lower section when the wound dressing dresses the wound the lower section is presented by a layer of loose particles or fibres of the bioresorbable material positioned on the wound.
  • the lower wound dressing layer may be a gel comprising the bioresorbable material coated onto the wound or one or more lower wound dressing sheets laid over the wound.
  • the bioresorbable material of the lower wound dressing layer is in fibre form, for example supported in a matrix such as a gel matrix formed from hyaluronic acid.
  • the lower wound dressing layer may take the form of one or more lower wound dressing fibre sheets, for example formed from non- woven fibres in which case the lower surface of the lower wound dressing layer may to advantage be roughened to expose ends of the fibres.
  • the bioresorbable material of the lower section is a polymer.
  • the polymer is protein-free, examples of which being poly(3-hydroxybutyrate) (PHB), polylactic acids, polyglycoUc acid, copolymers of glycolic acid and lactic acid, copolymers of lactic acid and ⁇ -aminocapronic acid, lactide polymers, polydesoxazon, copolymers of poly(3-hydroxybutyrate) and 3-hydroxyvalerate, polyesters of succinic acid and cross-linked hyaluronic acid.
  • PHB poly(3-hydroxybutyrate)
  • polylactic acids polyglycoUc acid
  • copolymers of glycolic acid and lactic acid copolymers of lactic acid and ⁇ -aminocapronic acid
  • lactide polymers polydesoxazon
  • copolymers of poly(3-hydroxybutyrate) and 3-hydroxyvalerate polyesters of succinic acid and cross-linked hyaluronic acid.
  • a protein-free bioresorbable polymer in the lower section appears to stimulate healing during degradation by stimulating macrophages, by forming a barrier against the surrounding and working as a scaffold for ceU growth.
  • the macrophage invasion caused by protein-free polymers covers the wound with tissue and controls the wound pain effectively in the first day or two. Vascularization and microcirculation occur, again stimulated by the polymer.
  • degradation of certain protein-free polymers such as PHB has a bacteriostatic and fungistatic effect and facUitates the wound heaUng of skin.
  • the invading macrophages also have a bactericidal effect.
  • the wound dressing can be left in place for a longer period owing to the bacteriostatic and fungistatic properties and the wound healing environment created beneath the dressing. Fewer changes of dressing means less disturbance of the healing process and less pain for the patient.
  • Poly(3-hydroxybutyrate) is the preferred material for the lower section because Applicant has found that PHB has the abUity to attract macrophages to the wound site at a greater rate than other polymers tested. The PHB also appears to lead to an increased vascularization, perhaps through a macrophage effect promoted by the PHB. In addition, the dressing period is further enhanced when PHB is used due to the fact that the bacteriostatic and fungistatic properties increase over time with the degradation of the PHB.
  • the lower section is formed as a fibrous PHB sheet, for instance a non-woven sheet, having hydrophobic fibres
  • the nature of the PHB fibres is such that the sheet has a capUlary capacity which aids in the exudate being drawn away from the wound and retained in the region between the sheet and the upper section.
  • a non-woven PHB fibre sheet wUl sweU during the first ten days or so by adding blood components and ceUs from the surrounding tissue owing to its construction despite the fibres being hydrophobic.
  • poly(3-hydroxybutyrate) is selected oligo(3-hydroxybutyrate), e.g. having 3 to 10 monomer units, may also be included in the lower section or may constitute the lower section.
  • the wound dressing is flexible thereby enabUng the dressing to follow the contour of the wound, for example a recessed wound.
  • the lower wound dressing layer is adapted to foUow the contour of the wound, for example by being flexible.
  • the lower section of the various forms of wound dressing according to the invention may support one or more growth factors.
  • the upper wound dressing layer of the wound dressing comprises a polymeric material.
  • the polymeric material may be bioresorbable and may further be protein-free.
  • the upper section may comprise poly(3-hydroxybutyrate).
  • the upper section may comprise a non- bioresorbable non-biodegradable material, non-limiting polymeric examples being polyurethane and polytetrafluoroethylene.
  • the upper section of the wound dressing is porous. Where the upper and lower sections are both porous the pore size of the pores of the upper section wiU be less than the pore size of the pores of the lower section. TypicaUy, the pore size of the upper section wiU be less than about 0.25 ⁇ ra
  • the wound dressing presents an adhesive edge for releasably adhering to a surface of the tissue structure adjacent the wound. This facUitates application and removal of the dressing or the upper part thereof.
  • the upper wound dressing layer presents the adhesive edge in which case the upper wound dressing layer may completely surround the lower wound dressing layer.
  • An ideal overlap margin is approximately 10 to 15 mm.
  • the adhesive edge may be presented by the intermediate section of the upper wound dressing layer.
  • the intermediate wound dressing layer presents the adhesive edge.
  • a method of treatment of a wound on a tissue structure of a Uving human or animal body comprising the steps of applying to the wound a fluid permeable lower layer of a bioresorbable material which promotes healing processes in the wound and overlaying the lower layer with a vapour permeable, bacteria impermeable upper layer.
  • the invention further provides a method for the manufacture of a wound dressing comprising the steps of coupUng a fluid permeable layer of a bioresorbable material which promotes healing processes in a wound to a vapour permeable, bacteria impermeable layer.
  • Fig. 1 is a cross-sectional side view of a first wound dressing in accordance with the present invention
  • Fig. 2 is a cross-sectional side view of a second wound dressing in accordance with the present invention.
  • Fig. 3 is a cross-sectional side view of a third wound dressing in accordance with the present invention.
  • a wound dressing 10 in accordance with the present invention comprises a layer 1 of a bioresorbable material which promotes wound healing processes, in this case poly(3-hydroxybuty ⁇ ate) (hereinafter "PHB"), applied to a skin wound 2 in the form of a fibrous non-woven sheet substantially free of volatile solvent, and an exterior microporous layer 3 of a polyurethane polymer.
  • PHB poly(3-hydroxybuty ⁇ ate)
  • the pores of the exterior polymer layer 3 have a pore size of less than 0.22 ⁇ m. This renders the layer 3 permeable to vapour and gases whUst maintaining the layer 3 essentiaUy impermeable to bacteria.
  • the dressing 10- may be conveniently applied and removed and further provides thermal insulation to maintain the body temperature in the vicinity of the wound surface by virtue of the exterior polymer layer 3.
  • the dressing 10 also keeps the wound 2 moist yet, by being permeable to moisture vapour, enables removal of excessive fluid from the wound 2. This prevents the nerve endings in the wound from drying out and concomitantly a cause of pain to the patient
  • the exterior polymer layer 3 has an adhesive edge 4.
  • the PHB fibres in the dressing 10 exhibit hydrophobic properties. The nature of the PHB fibres is such that exudate is drawn away from the wound 2 and retained in the PHB layer 1 and space between the PHB layer 1 and the exterior polymer layer 3.
  • the wound dressing 10 may be left in place for a relatively long period. This means that fewer changes of dressing are needed than with hitherto proposed dressings. This avoids disturbing the healing process with less pain for the patient.
  • One possibUity when changing the dressing 10 would be to remove the exterior layer of polymer 3 and excess exudate only, then put a fresh exterior layer 3 in place without disturbing the PHB layer 1.
  • most of the PHB layer 1 may be removed as weU and replaced by a fresh piece of PHB, with fibres of PHB that are adhering to the wound 2 being left.
  • a second wound dressing 110 in accordance with the present invention which comprises a layer 101 of PHB applied to a skin wound 102 in the form of a fibrous non-woven sheet substantiaUy free of volatile solvent and an exterior microporous layer 103 of a polyurethane polymer.
  • the PHB layer 101 is in the form of a patch completely surrounded by the exterior polymer layer 103 with a 10 to 15 mm margin (m) of the exterior polymer layer 103 around the PHB patch 101 being left.
  • the size of the PHB patch 101 itself may vary according to the size of the wound 102.
  • arrintermediate absorbent layer 105 of a hydrocoUoid material is provided. This absorbs exudate that is transported away from the wound 102 by the PHB patch 101 and promotes the transport away of further exudate.
  • the microporosity of the polyurethane exterior layer 103 means that the exudate can be slowly dispersed whUe still keeping the wound 102 moist and at the same time excluding bacteria. Vapour from the skin surrounding the wound 102 will also be able to pass through the exterior polymer layer 103.
  • a third wound dressing 210 in accordance with the present invention comprises a layer 201 of PHB appUed to a skin wound 202 in the form of a fibrous non ⁇ woven sheet substantially free of volatile solvent and an exterior microporous layer 203 of a polyurethane polymer.
  • the PHB is again in the form of a patch completely surrounded by the exterior polymer layer 203 with a 10 to 15 mm margin (m) of the polymer left around the PHB patch.
  • An intermediate absorbent layer 205 of a hydrocoUoid material is again provided, but in this case the hydrocoUoid layer 205 is made integral with the exterior polymer layer 203.
  • the hydrocoUoid material is adhesive to the skin, it may be stuck to the skin by its edge 204.
  • the hydrocoUoid performs the dual function of intermediate absorbent layer and adhesive edge to the exterior layer 203.
  • the dressing should be permeable to vapour but impermeable to bacteria.
  • the dressing should be absorbent and breathable.
  • the dressing should be easy to apply and, where needed, to remove. • The dressing should stimulate healing.
  • the dressing should comply with other treatments, for example allowing an outer com ⁇ pressing bandage to be provided and for effective debridement of dead skin to occur.
  • the dressing should be biocompatible and non-toxic.
  • TM dressing comprising a sheet of polyurethane (Tagerderm ) were used to dress a skin wound of a mammaUan body.
  • the dressing in accordance with the invention consisted of a lower section in the form of a non-woven fibre sheet of PHB and an upper section of a polyurethane sheet
  • the wound dressing of the invention produced an improved healed wound compared to the polyurethane sheet wound dressing. This was characterised by the healed wound covered by the wound dressing of the invention having a thicker and better quality layer of epithelial ceUs in the regenerated tissue than in the healed wound covered by the polyurethane sheet wound dressing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un pansement (10; 110; 210) pour panser une blessure (2; 102, 202) sur une structure tissulaire d'un corps humain ou animal. Ce pansement comporte une section (1; 101; 201) qui, lorsqu'il est appliqué sur la blessure, est adjacente à cette dernière, cette section inférieure étant perméable aux fluides et comprenant un matériau biorésorbable qui accélère le processus de cicatrisation, et une section supérieure (3; 103; 203) qui, lorsque le pansement est appliqué sur la blessure, recouvre la section inférieure, cette section supérieure étant perméable à la vapeur et imperméable aux bactéries. Ce pansement peut présenter une structure monobloc, une structure intégrée ou bien il peut être formé lors du pansage de la blessure.
PCT/SE1997/000946 1996-06-03 1997-05-30 Pansement WO1997046265A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ332950A NZ332950A (en) 1996-06-03 1997-05-30 Wound dressing with lower section adjacent to wound to promote healing of wound, and upper section being permeable to vapor and impermeable to bacteria
CA002255627A CA2255627A1 (fr) 1996-06-03 1997-05-30 Pansement
JP10500486A JP2000511446A (ja) 1996-06-03 1997-05-30 創傷用包帯
PL97330307A PL330307A1 (en) 1996-06-03 1997-05-30 Wound dressing
IL12710797A IL127107A0 (en) 1996-06-03 1997-05-30 Wound dressing
BR9709639A BR9709639A (pt) 1996-06-03 1997-05-30 Curativo para feridas processos de tratamento de uma ferida sobre uma estrutura de tecido de um organismo de ser humano ou animal vivo e de fabricação do curativo e uso de poli(3-hidroxibutirato) na forma de fibras ou de pó substancialmente isento de solvente volável
EP97926340A EP0906126A1 (fr) 1996-06-03 1997-05-30 Pansement
AU31128/97A AU719419C (en) 1996-06-03 1997-05-30 Wound dressing
IS4898A IS4898A (is) 1996-06-03 1998-11-19 Sáraumbúðir
NO985628A NO985628L (no) 1996-06-03 1998-12-02 SÕrbandasje
SE9804184A SE9804184L (sv) 1996-06-03 1998-12-03 Sårförband

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602200A SE9602200D0 (sv) 1996-06-03 1996-06-03 Wound dressing
SE9602200-9 1996-06-03

Publications (1)

Publication Number Publication Date
WO1997046265A1 true WO1997046265A1 (fr) 1997-12-11

Family

ID=20402870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1997/000946 WO1997046265A1 (fr) 1996-06-03 1997-05-30 Pansement

Country Status (20)

Country Link
EP (1) EP0906126A1 (fr)
JP (1) JP2000511446A (fr)
KR (1) KR20000016251A (fr)
CN (1) CN1226178A (fr)
AR (1) AR007386A1 (fr)
BR (1) BR9709639A (fr)
CA (1) CA2255627A1 (fr)
CZ (1) CZ388398A3 (fr)
HU (1) HUP0003151A3 (fr)
ID (1) ID17733A (fr)
IL (1) IL127107A0 (fr)
IS (1) IS4898A (fr)
NO (1) NO985628L (fr)
NZ (1) NZ332950A (fr)
PL (1) PL330307A1 (fr)
SE (1) SE9602200D0 (fr)
TR (1) TR199802501T2 (fr)
TW (1) TW347318B (fr)
WO (1) WO1997046265A1 (fr)
ZA (1) ZA974846B (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781679A1 (fr) * 1998-07-31 2000-02-04 Lhd Lab Hygiene Dietetique Nouveau pansement hydrocellulaire etanche et utilisation d'une masse adhesive hydrocolloide
WO2000051536A2 (fr) * 1999-03-02 2000-09-08 Meyer Schwarz Tatjana Pansement adhesif dote de protuberances et destine a etre applique sur la peau
WO2002030478A2 (fr) * 2000-10-13 2002-04-18 Cambridge Meditech Limited Ameliorations en detection
WO2002072163A1 (fr) * 2000-12-29 2002-09-19 Kimberly-Clark Worldwide, Inc. Pansement bioabsorbable
US7619130B2 (en) 2000-07-18 2009-11-17 Coloplast A/S Multi-layer wound dressing formed as a single unit
US7960602B2 (en) 2004-12-30 2011-06-14 Bayer Innovation Gmbh Compositions and processes for accelerated wound healing using novel fibrous webbings
CN103170005A (zh) * 2011-12-23 2013-06-26 闳晖实业股份有限公司 伤口敷料
US8790688B2 (en) 2001-12-21 2014-07-29 Coloplast A/S Wound care device for local treatment of pain in a wound
WO2015186101A1 (fr) * 2014-06-05 2015-12-10 University Of The Witwatersrand, Johannesburg Pansement
US11278640B2 (en) 2016-05-04 2022-03-22 Coloplast A/S Adhesive wafer with a neutralizer matrix
US11491254B2 (en) 2017-11-08 2022-11-08 Coloplast A/S Adhesive wafer with a neutralizer matrix
US11911310B2 (en) 2017-11-08 2024-02-27 Coloplast A/S Adhesive wafer with a neutralizer matrix

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) * 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
CN1809390B (zh) * 2003-06-26 2010-11-17 株式会社瑞光 创伤覆盖材料和创伤覆盖材料成套器具
US9561136B2 (en) 2014-03-13 2017-02-07 Gregory Troy Williams Bandage
KR101577140B1 (ko) 2014-06-30 2015-12-11 박성훈 필름형 용해성 창상피복재
CN105688260A (zh) * 2016-03-21 2016-06-22 江苏广达医材集团有限公司 一种生物可降解医用腹部手术伤口敷料
CN105816903A (zh) * 2016-05-12 2016-08-03 东华大学 一种载药透明质酸纳米纤维复合敷料及其制备方法
CN109125781B (zh) * 2018-11-16 2021-09-07 南阳市中心医院 一种肝胆外科抗菌敷料

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118068A (en) * 1982-03-31 1983-10-26 Delalande Sa Artificial skin
GB2166354A (en) * 1984-10-10 1986-05-08 Ici Plc Wound dressings
US4603070A (en) * 1984-10-03 1986-07-29 Imperial Chemical Industries Plc Non-woven fibrous materials
EP0349505A2 (fr) * 1988-06-27 1990-01-03 Astra Aktiebolag Matériau chirurgical
EP0599589A1 (fr) * 1992-11-23 1994-06-01 JOHNSON & JOHNSON MEDICAL, INC. Pansement

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2118068A (en) * 1982-03-31 1983-10-26 Delalande Sa Artificial skin
US4603070A (en) * 1984-10-03 1986-07-29 Imperial Chemical Industries Plc Non-woven fibrous materials
GB2166354A (en) * 1984-10-10 1986-05-08 Ici Plc Wound dressings
EP0349505A2 (fr) * 1988-06-27 1990-01-03 Astra Aktiebolag Matériau chirurgical
EP0599589A1 (fr) * 1992-11-23 1994-06-01 JOHNSON & JOHNSON MEDICAL, INC. Pansement

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007635A1 (fr) * 1998-07-31 2000-02-17 Laboratoires D'hygiene Et De Dietetique Pansement hydrocellulaire avec une masse adhesive hydrocolloide
FR2781679A1 (fr) * 1998-07-31 2000-02-04 Lhd Lab Hygiene Dietetique Nouveau pansement hydrocellulaire etanche et utilisation d'une masse adhesive hydrocolloide
WO2000051536A2 (fr) * 1999-03-02 2000-09-08 Meyer Schwarz Tatjana Pansement adhesif dote de protuberances et destine a etre applique sur la peau
WO2000051536A3 (fr) * 1999-03-02 2002-10-24 Tatjana Meyer-Schwarz Pansement adhesif dote de protuberances et destine a etre applique sur la peau
US7619130B2 (en) 2000-07-18 2009-11-17 Coloplast A/S Multi-layer wound dressing formed as a single unit
US7611860B2 (en) 2000-10-13 2009-11-03 Cambridge Meditech Limited Indicator for in-situ detecting of lysozyme
WO2002030478A2 (fr) * 2000-10-13 2002-04-18 Cambridge Meditech Limited Ameliorations en detection
WO2002030478A3 (fr) * 2000-10-13 2002-07-25 Cambridge Meditech Ltd Ameliorations en detection
WO2002072163A1 (fr) * 2000-12-29 2002-09-19 Kimberly-Clark Worldwide, Inc. Pansement bioabsorbable
KR100860896B1 (ko) * 2000-12-29 2008-09-29 킴벌리-클라크 월드와이드, 인크. 생흡수성 상처 드레싱
US7041868B2 (en) 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Bioabsorbable wound dressing
US8790688B2 (en) 2001-12-21 2014-07-29 Coloplast A/S Wound care device for local treatment of pain in a wound
AU2005321677B2 (en) * 2004-12-30 2011-10-27 Bayer Innovation Gmbh Shortened wound healing processes by means of novel fiber non-wovens
US8088965B2 (en) 2004-12-30 2012-01-03 Bayer Innovation Gmbh Method for accelerated wound healing using novel fibrous webbings
US7960602B2 (en) 2004-12-30 2011-06-14 Bayer Innovation Gmbh Compositions and processes for accelerated wound healing using novel fibrous webbings
CN103170005A (zh) * 2011-12-23 2013-06-26 闳晖实业股份有限公司 伤口敷料
WO2015186101A1 (fr) * 2014-06-05 2015-12-10 University Of The Witwatersrand, Johannesburg Pansement
US10080816B2 (en) 2014-06-05 2018-09-25 University Of The Witwatersrand, Johannesburg Wound dressing
US11278640B2 (en) 2016-05-04 2022-03-22 Coloplast A/S Adhesive wafer with a neutralizer matrix
US11491254B2 (en) 2017-11-08 2022-11-08 Coloplast A/S Adhesive wafer with a neutralizer matrix
US11786631B2 (en) 2017-11-08 2023-10-17 Coloplast A/S Ostomy appliance having a neutralizing layer deposited on adhesive of a wafer and located inside a waste collection bag
US11911310B2 (en) 2017-11-08 2024-02-27 Coloplast A/S Adhesive wafer with a neutralizer matrix

Also Published As

Publication number Publication date
IL127107A0 (en) 1999-09-22
TR199802501T2 (xx) 1999-02-22
NZ332950A (en) 2000-05-26
JP2000511446A (ja) 2000-09-05
AU3112897A (en) 1998-01-05
HUP0003151A2 (hu) 2001-02-28
KR20000016251A (ko) 2000-03-25
AU719419B2 (en) 2000-05-11
EP0906126A1 (fr) 1999-04-07
SE9602200D0 (sv) 1996-06-03
HUP0003151A3 (en) 2002-05-28
NO985628L (no) 1999-02-03
TW347318B (en) 1998-12-11
IS4898A (is) 1998-11-19
CZ388398A3 (cs) 1999-04-14
BR9709639A (pt) 1999-08-10
NO985628D0 (no) 1998-12-02
CA2255627A1 (fr) 1997-12-11
ZA974846B (en) 1998-12-02
PL330307A1 (en) 1999-05-10
ID17733A (id) 1998-01-22
AR007386A1 (es) 1999-10-27
CN1226178A (zh) 1999-08-18

Similar Documents

Publication Publication Date Title
EP0906126A1 (fr) Pansement
KR100860896B1 (ko) 생흡수성 상처 드레싱
US8303551B2 (en) Wound dressings
WO1995005204A1 (fr) Matiere poreuse non fibreuse, pansement comprenant une telle matiere et procede de fabrication de cette derniere
US20060211972A1 (en) Wound dressing
WO1994017840A1 (fr) Compositions pharmaceutiques comprenant une substance spongieuse composee de derives ester d'acide hyaluronique en combinaison avec d'autres substances pharmacologiquement actives
JP7429996B2 (ja) 微小構造を含む組織処置デバイス
JPS62246370A (ja) 創傷被覆材
AU719419C (en) Wound dressing
Mao et al. Nonwoven wound dressings
RU2240140C2 (ru) Медицинская многослойная повязка и изделия на ее основе
US20120015022A1 (en) Biodegradable wound care products with biocompatible artificial skin treatment
JPH0751139B2 (ja) 創傷被覆材
MXPA98010047A (en) Aposito for heri
JP2001212170A (ja) 創傷被覆材
JPH0481466B2 (fr)
JP2002200110A (ja) 創傷被覆材
RU2189210C1 (ru) Многослойная медицинская повязка
JPH03206032A (ja) 創傷被覆材
JPH0560943B2 (fr)
JP2001017532A (ja) 創傷被覆材
JP2001017531A (ja) 創傷被覆材

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97196710.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 332950

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2255627

Country of ref document: CA

Ref document number: 2255627

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1998-3883

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/010047

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998/02501

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1019980709824

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 98041841

Country of ref document: SE

WWE Wipo information: entry into national phase

Ref document number: 1997926340

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 98041841

Country of ref document: SE

WWP Wipo information: published in national office

Ref document number: 1997926340

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-3883

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980709824

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997926340

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-3883

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019980709824

Country of ref document: KR